Replies to post #173339 on Anavex Life Sciences Corp (AVXL)

[XenaLives]

Interesting as was this article listed at the bottom:

This Phase III is the money shot for Alkermes. The research group already produced positive Phase III data underscoring that their antipsychotic drug performed better than a placebo while proving statistically about the same as generic olanzapine alone. Weight gain is a routine side effect for their drug, but they’re looking to replace a standard therapy with one that can guard a greater percentage of patients from putting on pounds during treatment.

https://endpts.com/after-getting-beat-up-on-its-depression-drug-pitch-a-battered-alkermes-pivots-to-schizophrenia-with-a-positive-phiii-readout-but-skeptics-are-ready-to-pounce/